Verrica is advancing its lead product VP-102, a proprietary topical therapy, in many common skin indications including Molluscum contagiosum and Verruca Vulgaris (common warts and plantar warts). Our lead product VP-102 is a topical that is applied directly to the lesions. VP-102 is designed to be convenient for both patients and practitioners. Verrica is also pursuing additional common dermal and non-dermal indications.
We are initiating two Phase 3 trials in molluscum contagiosum under NCT03377803 and NCT03377790.